Epistasis Blog

From the Artificial Intelligence Innovation Lab at Cedars-Sinai Medical Center (www.epistasis.org)

Friday, January 12, 2007

Genetic Architecture of Plasma t-PA and PAI-1

We have several papers recently published or in press that report results from our genetic studies of plasma levels of tissue plasminogen activator (t-PA) [OMIM 173370] and plasminogen activator inhibitor 1 (PAI-1) [OMIM 173360] in Caucasians from the PREVEND study in The Netherlands. The latest paper to be published in Genomics reports epistatic effects. Papers on gene-environment interaction and high-order epistatic effects are planned.

Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost. 2006 Oct;96(4):471-7. [PubMed]

Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Gender-specific correlations of PAI-1 and t-PA levels with cardiovascular disease-related traits. J Thromb Haemost 2007, in press. [PubMed]

Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 2007, in press. [PubMed]

This work was supported by NIH grant HL65234 (PI - Moore)

0 Comments:

Post a Comment

<< Home